Statin induced neuropathy: Myth or reality?;Neuropathies aux statines, mythe ou réalité?

Revue Neurologique

Volumn 162, Issue 12, 2006, Pages 1286-1289

  Formaglio, M ^a   Vial, C ^a  

^a HÔPITAL NEUROLOGIQUE   (France)

Author keywords

Hydromethylglutaryl Co A reductase; Neurotoxicity; Peripheral neuropathy

Indexed keywords

CORTICOSTEROID; CREATINE KINASE; CYCLOSPORIN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; MEVINOLIN; MYELIN; NICOTINIC ACID; PRAVASTATIN; PROTEINASE INHIBITOR; PYRROLE DERIVATIVE; SIMVASTATIN;

AREFLEXIA; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CONFERENCE PAPER; CREATINE KINASE BLOOD LEVEL; CYTOLYTIC HEPATITIS; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE RESPONSE; DRUG ERUPTION; DRUG SAFETY; DYSESTHESIA; HUMAN; HYPERLIPIDEMIA; HYPOTHESIS; IDIOPATHIC DISEASE; LONG TERM EXPOSURE; MONONEUROPATHY; MYALGIA; NERVE FIBER DEGENERATION; NERVE FUNCTION; NERVE MEMBRANE; NEUROPATHY; NEUROTOXICITY; PARESTHESIA; POLYNEUROPATHY; PROSPECTIVE STUDY; RHABDOMYOLYSIS; SENSORIMOTOR NEUROPATHY; SIDE EFFECT; TREATMENT DURATION;

EID: 33845796534     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0035-3787(06)75148-7     Document Type: Conference Paper

References (16)

1. AHMAD S. (1995). Lovastatin and peripheral neuropathy. American Heart Journal, 130: 1321.
2. BRASS LM, ALBERTS MJ, SPARKS L. (2006). An assessment of stain safety by neurologist. Am J Cardiol, 97(suppl): 86C-88C.
3. CORRAO G, ZAMBON A, BERTÙ L, BOTTERI E, LEONI O, CONTIERO P. (2004). Lipid lowering drugs prescription and risk of peripheral neuropathy: an exploratory case-control study using automated databases. J Epidemiol Community Health, 58: 1047-1051.
4. DONAGHY M. (2002). Assessing the risk of drug-induced neurologic disorders: statins and neuropathy. Neurology, 58: 1321-1322.
5. GAIST D, GARCIA RODRIGUEZ LAA, HUERTA C, HALLAS J, SINDRUP SH. (2001). Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? Eur J Clin Pharmacol, 56: 931-933.
6. GAIST D, JEPPESEN U, ANDERSEN M, GARCIA RODRIGUEZ LA, HALLAS J, SINDRUP SH. (2002). Statins and risk of polyneuropathy: a case control study. Neurology, 58: 1333-1337.
7. HEART PROTECTION STUDY COLLABORATIVE GROUP. (2004). Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20.536 people with cerebrovascular disease or other high-risk conditions. Lancet, 363: 757-767.
8. JACOBS MB. (1994). HMG-CoA reductase inhibitor therapy and peripheral neuropathy. Ann Int Med, 120: 970.
9. JEPPESEN U, GAIST D, SMITH T, SINDRUP SH. (1999). Statins and peripheral neuropathy. Eur J Clin Pharmacol, 54: 835-838.
10. LEIS AA, STOKIC DS, OLIVIER J. (2005). Statins and polyneuropathy: setting the record straigh. Muscle Nerve, 32: 428-430.
11. LO YL, LEOH TH, LOH LM, TAN CE. (2003). Statin therapy and small fibre neuropathy: a serial electrophysiological study. J Neurol Sci, 208: 105-108.
12. MC KENNEY JM, PHARMD, DAVIDSON MH, JACOBSON TA, GUYTON JR. (2006). Final conclusions and recommendations of the national lipid association statin safety assessment task force. Am J cardiol, 97(suppl): 89C-94C.
13. PHAN T, MCLEOD JG, POLLARD JD, PEIRIS O, ROHAN A, HALPERN JP. (1995). Peripheral neuropathy associated with simvastatin. J Neurol Neurosurg Psychiatry, 58: 625-628.
14. RAJABALLY YA, VARAKANTAM V, ABBOT RJ. (2004). Disorder ressembling Guillain-Barré syndrome on initiation of statin neuropathy. Muscle Nerve, 30: 663-666.
15. SCOLA RH, TRENTIN AP, GERMINIANI FMB, PIOVESAN EJ, WERNECK LC. (2004). Simvastatin-induced mononeuroapthy multiplex. Arq Neuropsiquiatr, 62: 540-542.
16. SILVERBERG C. (2003). Atorvastatin-induced polyneuropathy. Ann Int Med, 139: 792-793.